FDA approves bimatoprost (Lumigan) for treatment of eyelash hypotrichosis

The glaucoma drug bimatoprost has been approved by the Food and Drug Administration for the treatment of eyelash hypotrichosis (la shes that are not long, thick or dark enough). The drug will be marketed under the name of Latisse and is applied to the base of the upper eyelashes and increases growth within eight to 10 weeks.